Journal for ImmunoTherapy of Cancer最新收录文章列表-丁香通

大类医学

小类免疫学、肿瘤学

EISSN2051-1426

最新文献

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma

PMID: 421442612026-05-17

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma

PMID: 421407432026-05-15

Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma

PMID: 421348992026-05-14

Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer

PMID: 421349002026-05-14

Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic

PMID: 421285202026-05-13

First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer

PMID: 421285182026-05-13

Feeder-free generation of functional dendritic cells from human pluripotent stem cells

PMID: 421285222026-05-13

Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response

PMID: 421201812026-05-12

CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors

PMID: 421201802026-05-12

Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer

PMID: 421149502026-05-11

Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis

PMID: 421149512026-05-11

LGALS9 blockade augments vaccine-induced immune responses against prostate cancer

PMID: 421033552026-05-08

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies

PMID: 421033562026-05-08

Sensory neuron-derived CCL5 orchestrates an immunosuppressive niche via regulatory T cells to fuel head and neck tumor progression

PMID: 421033582026-05-08

Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy

PMID: 420978352026-05-07

Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma

PMID: 420863092026-05-05

Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer

PMID: 420822702026-05-04

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer

PMID: 420822712026-05-04

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases

PMID: 420822732026-05-04

Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma

PMID: 420822692026-05-04

大家都在搜

大家都在搜